18-19-3　ⓔ文献

  1. Hafer–Macko C, Hsieh ST, et al: Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol, 1996; 40: 635–644.

  2. Mitsui Y, Kusunoki S, et al: A multicenter prospective study of Guillain–Barré syndrome in Japan: a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry, 2015; 86: 110–114.

  3. Kusunoki S, Chiba A, et al: N–acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain–Barré syndrome. Ann Neurol, 1994; 35: 570–576.

  4. van Doorn PA, Ruts L, et al: Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol, 2008; 7: 939–950.

  5. Chiba A, Kusunoki S, et al: Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol, 1992; 31: 677–679.

  6. Kaida K, Kamakura K, et al: GD1b–specific antibody induces ataxia in Guillain–Barré syndrome. Neurology, 2008; 71: 196–201.

  7. Leonhard SE, Mandarakas MR, et al: Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol, 2019; 15: 671–683.

  8. Yuki N, Taki T, et al: A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside–like structure. J Exp Med, 1993; 178: 1771–1775.

  9. Kusunoki S, Shiina M, et al: Anti–Gal–C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology, 2001; 57: 736–738.

  10. 荻野美恵子，斎藤豊和，他：Guillain–Barré症候群の全国調査―第3次調査結果を含めた最終報告．厚生労働省特定疾患対策研究事業　免疫性神経疾患に関する調査研究班　平成12年度研究報告書，2000; 99–101.

  11. Susuki K, Rasband MN, et al: Anti–GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci, 2007; 27: 3956–3967.

  12. Samukawa M, Hamada Y, et al: Clinical features in Guillain–Barré syndrome with anti–Gal–C antibody. J Neurol Sci, 2014; 337: 55–60.

  13. Snyder LA, Rismondo V, et al: The Fisher variant of Guillain–Barré syndrome (Fisher syndrome). J Neuro–Ophthalmol, 2009; 29: 312–324.

  14. Chiba A, Kusunoki S, et al: Serum anti–GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barre syndrome: Clinical and immunohistochemical studies. Neurology, 1993; 43: 1911–1917.

  15. Yoshikawa K, Kuwahara M, et al: Varied antibody reactivities and clinical relevance in anti–GQ1b antibody–related diseases. Neurol Neuroimmunol Neuroinflamm, 2018; 5: e501.

  16. Plomp JJ, Molenaar PC, et al: Miller Fisher anti–GQ1b antibodies: alpha-latrotoxin–like effects on motor end plates. Ann Neurol, 1999; 45: 189–199.

  17. Kaida K, Kusunoki S, et al: Anti–GQ1b antibody as a factor predictive of mechanical ventilation in Guillain–Barré syndrome. Neurology, 2004; 62: 821–824.

  18. Halstead SK, Zitman FM, et al: Eculizumab prevents anti–ganglioside antibody–mediated neuropathy in a murine model. Brain, 2008; 131: 1197–1208.

  19. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Lancet, 1997; 349: 225–230.

  20. Misawa S, Kuwabara S, et al: Japanese Eculizumab Trial for GBS (JET–GBS) Study Group. Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicentre, double–blind, randomised phase 2 trial. Lancet Neurol, 2018; 17: 519–529.

  21. Querol L, Nogales–Gadea G, et al: Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology, 2014; 82: 879–886.

  22. Iijima M, Koike H, et al: Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry, 2008; 79: 1040–1043.

  23. van Schaik I, Bril V, et al: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): A randomised, double–blind, placebo–controlled, phase 3 trial. Lancet Neurol, 2018; 17: 35–46.

  24. Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first Revision. J Peripher Nerv Syst, 2010; 15: 295–301.